The economic evaluation of nitrous oxide in sevoflurane anesthesia

Department of Anesthesiology and Pain Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea

Deokkyu Kim, Jiyoun Oh, Wonyoung Choi, Young Jun Kwon, and Seonghoon Ko

Background: Nitrous oxide (N₂O) is much cheaper than recently introduced volatile anesthetics such as sevoflurane and desflurane, and can reduce the consumption of these anesthetics. The use of N₂O is under current debate. The purpose of this study was to evaluate economic effect of 50% N₂O during sevoflurane anesthesia in Korea.

Methods: Seventy patients were randomly allocated to Group A or Group N. Anesthesia induction was performed using propofol, rocuronium, and 3-5% of sevoflurane with air (Group A) or 50% N₂O (Group N). Fresh gas flow (FGF) was 6 L/min during induction, and 3 L/min for maintenance. Mean arterial pressure (MAP), heart rate (HR), bispectral index (BIS), and minimum alveolar concentration (MAC) were recorded. The consumption of sevoflurane was measured at every 10 minutes for the first 1 hour. The economic effect was analyzed based on the payment criterion of Korean National Health Insurance Service.

Results: MAP, HR, BIS, and MAC showed no differences between the two groups. The sevoflurane consumptions for the first 1 hour were 39.2 ± 6.3 ml in Group A and 29.2 ± 4.9 ml in Group N (P < 0.01); and the N₂O consumption was 93.7 ± 1.5 L in Group N. The total costs of inhaled anesthetics were 16,190 (14.8 USD) and 13,062 (12.0 USD) Korean won for the first 1 hour in Groups A and N, respectively.

Conclusions: Use of 50% N₂O with 3 L/min FGF reduced the sevoflurane consumption by 25% and anesthetic cost by 20% for the first 1 hour. (Anesth Pain Med 2017; 12: 23-27)

Key Words: Economics, Nitrous oxide, Sevoflurane.
specialized vaporizer (DIVATM, Zeus TM, Dräger Medical GmbH, Germany) that directly injects volatile anesthetic into the anesthesia circuit. The consumption was recorded every 10 minutes. The economic effect was analyzed based on the payment criterion of the Korean National Health Insurance Service (KNHIS). The criterion is 9.5 ml for the first 15 min and 5.0 ml per 15 min thereafter. The costs are 413 won/ml for sevoflurane and 10.7 won/L for N₂O in Korea (1 USD = 1,092 Korean won; Sep. 7. 2016 exchange rate). KNHIS generally pays 10,119 won for 24.5 ml of sevoflurane consumption and 1,926 won for 180 L of N₂O consumption during the first 1 h usage.

The calculated sample size based on the KNHIS payment criterion was 29 patients per group in order to detect difference in sevoflurane consumption of 30% for the first 1 h dose with a SD of 10 ml, using an alpha level of 0.05 and a power of 0.80. To allow for attrition, the total sample size was enlarged to 70. The analysis was performed using SigmaPlot 12.5 (Systat Software Inc., USA). Data were expressed as mean ± SD. Demographic data, clinical characteristics and cost of anesthetics were analyzed by a t-test or Mann-Whitney rank sum test depending on the results of the normality and equal variance test. Hemodynamics, BIS, MAC values, and anesthetic consumption were analyzed by two-way repeated measures ANOVA and Holm-Sidak method for post-hoc test. Statistical significance was considered at P < 0.05.

RESULTS

Six of 70 enrolled patients did not complete the study and were excluded from the statistical results. Those who had severe hypertension (3 patients), unmeasured BIS (2 patients), and difficult airway (1 patient) were dropped from the experiment. Thirty-three patients in Group A and 31 patients in Group N completed the study. Patients and clinical characteristics were shown in Table 1. Clinical characteristics showed no between-group differences.

MAP, HR, and BIS showed no difference between the two groups during overall experimental time (P = 0.734 for MAP, P = 0.699 for HR, and P = 0.703 for BIS) and at pre-induction, 5 min post-intubation, and 10, 30, and 60 min after skin incision (Table 2). MAC values were not different between the two groups (P = 0.128, Fig. 1).

The sevoflurane consumption was significantly lower in Group N (8.6 ± 1.6 ml) than Group A (10.1 ± 2.1 ml) at the first 10 min after sevoflurane administration (P = 0.003). Although sevoflurane consumption differences between groups
Table 1. Patients and Clinical Characteristics

|                      | Group A (n = 33) | Group N (n = 31) | P value |
|----------------------|------------------|------------------|---------|
| Sex (M/F)            | 8/25             | 7/24             | 0.890   |
| Age (yr)             | 48.2 ± 10.6      | 45.3 ± 10.8      | 0.314   |
| Height (cm)          | 159 ± 5.8        | 159 ± 6.2        | 0.883   |
| Weight (kg)          | 60.1 ± 7.4       | 62.4 ± 9.4       | 0.355   |
| Surgery time (min)   | 131.2 ± 56.8     | 136.2 ± 49.3     | 0.731   |
| Anesthesia time (min)| 150.9 ± 62.4     | 154.1 ± 50.7     | 0.839   |
| Time from sevoflurane administration to skin incision (min) | 19.0 ± 5.7 | 19.1 ± 6.5 | 0.926 |
| Surgery type         |                  |                  | 0.589   |
| Gynecologic          | 16               | 19               |         |
| Gastro-intestinal    | 10               | 7                |         |
| Hepatic              | 7                | 5                |         |

Data are expressed as mean ± SD or number of patient. Group A: received air and oxygen with 0.5 of inspired fraction of oxygen. Group N: received nitrous oxide and oxygen with 0.5 inspired fraction of oxygen.

Table 2. Vital Signs and Bispectral Index

|                      | Mean arterial pressure (mmHg) | Heart rate (beats/min) | Bispectral index |
|----------------------|------------------------------|------------------------|-----------------|
|                      | Group A (n = 33) | Group N (n = 31) | P value | Group A (n = 33) | Group N (n = 31) | P value | Group A (n = 33) | Group N (n = 31) | P value |
| Pre-induction        | 97.4 ± 12.5        | 94.8 ± 10.2           | 0.420   | 74.7 ± 13.2       | 78.0 ± 12.5       | 0.346   | 95.5 ± 2.1        | 95.2 ± 2.4        | 0.809   |
| 5 min after intubation | 84.2 ± 13.9       | 80.4 ± 8.7            | 0.202   | 86.1 ± 12.2       | 82.6 ± 11.9       | 0.304   | 43.2 ± 3.9        | 43.7 ± 3.6        | 0.634   |
| 10 min after skin incision | 89.7 ± 14.5    | 86.6 ± 10.6           | 0.327   | 80.1 ± 14.6       | 78.4 ± 14.0       | 0.284   | 44.8 ± 3.7        | 45.3 ± 4.4        | 0.718   |
| 30 min after skin incision | 80.2 ± 13.4    | 83.7 ± 12.5           | 0.278   | 72.6 ± 12.8       | 71.6 ± 14.4       | 0.768   | 45.1 ± 5.0        | 46.2 ± 5.8        | 0.330   |
| 60 min after skin incision | 84.9 ± 9.0     | 86.2 ± 12.0           | 0.505   | 70.6 ± 9.8        | 70.6 ± 12.7       | 0.942   | 45.0 ± 4.8        | 44.1 ± 4.4        | 0.513   |

Data are expressed as mean ± SD. Group A: received air and oxygen with 0.5 of inspired fraction of oxygen. Group N: received nitrous oxide and oxygen with 0.5 inspired fraction of oxygen.

A and N were changed, sevoflurane-sparing effect by the use of N2O was increased after the first 10 min (Table 3). For the first 1 h, sevoflurane consumptions were 39.2 ± 6.3 ml in Group A and 29.2 ± 4.9 ml in Group N (P < 0.01, Fig. 2). Fifty percent N2O with 3 L/min of FGF for anesthesia maintenance caused 25% reduction in the sevoflurane consumption. However, the KNHIS payment criterion of sevoflurane (24.5 ml/h) is lower than the sevoflurane consumptions with 3 L/min FGF for the first 1 h despite use of N2O. The N2O consumption for 1 h was 93.7 ± 1.5 L in Group N.

The economic analysis indicated that in Korea, the costs were 413 won/ml sevoflurane and 10.7 won/L N2O; and the overall cost of inhaled anesthetics was 16,190 Korean won (14.8 USD) and 13,062 Korean won (12.0 USD) in Groups A and N for the first 1 hour (P < 0.01), respectively (1 USD = 1,092 Korean won; Sep. 7. 2016 exchange rate).
Table 3. Sevoflurane Consumptions (ml) and Sevoflurane-sparing Effect by the Use of Nitrous Oxide

|                  | Group A (n = 33) | Group N (n = 31) | P value  | Sevoflurane-sparing percent (%) |
|------------------|------------------|------------------|----------|---------------------------------|
| 0-10 min         | 10.1 ± 2.1       | 8.6 ± 1.6        | 0.003    | 15                              |
| 10-20 min        | 4.9 ± 1.9        | 3.7 ± 1.4        | 0.015    | 24                              |
| 20-30 min        | 7.1 ± 2.4        | 5.2 ± 1.7        | < 0.001  | 27                              |
| 30-40 min        | 7.1 ± 2.8        | 4.6 ± 1.2        | < 0.001  | 35                              |
| 40-50 min        | 5.3 ± 1.8        | 3.8 ± 1.3        | 0.006    | 28                              |
| 50-60 min        | 4.7 ± 1.7        | 3.7 ± 1.6        | 0.037    | 21                              |

Data are expressed as mean ± SD. Group A: received air and oxygen with 0.5 of inspired fraction of oxygen. Group N: received nitrous oxide and oxygen with 0.5 inspired fraction of oxygen.

DISCUSSION

In the present study, 50% N₂O with 3 L/min of FGF caused 25% reduction in the sevoflurane consumption and 20% reduction in costs for the first 1 h. In Korea, the KNHIS payment criterion for inhaled anesthetics, unlike other agents, is based on anesthetic time and not amounts of consumed anesthetics. The KNHIS payment criterion for sevoflurane is 24.5 ml (413 won/ml, 10,119 won/h) for the first 1 h. The sevoflurane consumptions for the first 1 h with 3 L/min FGF in both groups (Group A: 39.2 ± 6.3 ml, Group N: 29.2 ± 4.9 ml) were greater than the KNHIS payment criterion. Our results suggested that < 3 L/min FGF is required to meet the KNHIS criterion, although 3 L/min FGF is most commonly used among Korean anesthesiologists [10]. However, 3 L/min FGF might be surplus due to advanced development of monitoring systems and anesthetic machines. If FGF is reduced, the volatile anesthetic-sparing and economic effects by N₂O are expected to be lessened. The current economic result was analyzed under Korean medical circumstance and anesthetic cost, hence, the results may not be applicable to other countries.

A previous clinical study on the volatile anesthetic-sparing effect by N₂O [9] showed that 66% N₂O spared sevoflurane consumption by 60% during short ambulatory knee arthroscopy, which is greater than result of our study, likely due to fentanyl administration (2 µg/kg) during anesthetic induction in the previous study. The sevoflurane-sparing effect by N₂O would be magnified because the sevoflurane requirement was decreased by fentanyl; furthermore, anesthetic duration (17 vs. 150 min), control of FGF rate, surgical invasiveness (knee arthroscopy vs. open abdominal surgery), and measurement technique (weighing of vaporizer vs. direct injected amount) could have caused differences in sevoflurane-sparing effect between studies.

Interaction between N₂O and inhaled anesthetics is complex. It is generally accepted that volatile anesthetics and N₂O act in an additive manner [11]. In the present study, the MAC values were calculated by summation of MAC values of sevoflurane and N₂O. Although the MAC values were changed during operation and for individual patients, the mean values were maintained at approximately 1.5 MAC in both groups. Because 50% N₂O has about 0.5 MAC, we expected about 33% sevoflurane-sparing effect by summation of MAC values of sevoflurane and N₂O. Contrary to expectation, the results indicated a 25% sevoflurane sparing effect. This discrepancy could be due to several factors. First, the patients received sevoflurane 3-5% with high FGF rate (6 L/min) after propofol administration. Therefore, 10.1 ml and 8.6 ml sevoflurane were consumed for the first 10 min in groups A and N,
respectively. The sevoflurane-sparing effect by the use of N\textsubscript{2}O was only 15\% during the first 10 min; and the effect was increased to 20-35\% during anesthesia maintenance. High sevoflurane concentration with high FGF rate during anesthesia induction may attenuate the anesthetic-sparing effect by N\textsubscript{2}O. Second, the administered sevoflurane concentration was not standardized, instead the concentration was adjusted widely by the surgical stimuli according to cardiovascular and BIS values. Sevoflurane-sparing effect was changed solely the variable concentration of administered sevoflurane; and since N\textsubscript{2}O concentration was fixed, the sevoflurane-sparing effect of N\textsubscript{2}O differed by surgical period. Despite lower total induction may attenuate the anesthetic-sparing effect by N\textsubscript{2}O.

Sevoflurane concentration with high FGF rate during anesthesia N\textsubscript{2}O might have differed from our current results.

\text{N}\textsubscript{2}O can increase the incidence of PONV. In the current study, the economic analysis was limited to cost of anesthetics alone since the cost of managing immediate postoperative complications by N\textsubscript{2}O was not evaluated. If the management cost of complications was included, the economic effect of N\textsubscript{2}O might have differed from our current results.

Several methods are available to measure the consumption of inhalation anesthetics. First method involves the difference in weight of the vaporizer before and after anesthesia divided by the density of inhalation anesthetic [9,12]. This method cannot serially measure the consumptions during anesthesia induction, maintenance, and emergence because of one time measurement after the end of anesthesia. Second method is based calculating the amount of consumption from the pharmacokinetics of the volatile agent. This method requires constant fresh gas flow and vaporizer setting [13]; and therefore, is difficult to apply in the clinical field. Third method is the measurement of consumption from specialized vaporizer, as in our study [14]. The unique vaporizer is located out of the gas flow circuit and directly injects volatile anesthetics into the circuit. Because the consumption of volatile anesthetics can be measured by this vaporizer in real time, sevoflurane consumption reflects the surgical stimuli in the present study.

Our study had some limitations. First, it was difficult to perform the double-blinded study; therefore, the amount of sevoflurane administered could be biased despite attempts to maintain adequate anesthesia according to hemodynamics and BIS value. Second, the type of surgery was not standardized; hence, although only patients scheduled for open abdominal surgeries were enrolled, the surgical invasiveness might differ by the type of surgery.

In conclusion, 50\% N\textsubscript{2}O with 3 L/min FGF reduced sevoflurane consumption by 25\% for the first 1 h. Economically, the total inhaled anesthetic cost was decreased by 20\%. The KNHS payment criterion of sevoflurane is lower than the sevoflurane consumptions with 3 L/min FGF for the first 1 h despite use of N\textsubscript{2}O.

\textbf{REFERENCES}

1. Hopkins PM. Nitrous oxide: a unique drug of continuing importance for anaesthesia. Best Pract Res Clin Anaesthesiol 2005; 19: 381-9.
2. Kim SH, Song JE, Chung KH, Lee HR, Kim MG, Yang HJ. The influence of nitrous oxide on postoperative bowel function recovery for gynecologic patients. Anesth Pain Med 2007; 2: 156-9.
3. Fernández-Guisasola J, Gómez-Arnau JL, Cabrera Y, del Valle SG. Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis. Anaesthesia 2010; 65: 379-87.
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
5. Sato Y, Kobayashi E, Murayama T, Mishima M, Seo N. Effect of N-methyl-D-aspartate receptor epsilon1 subunit gene disruption of the action of general anesthetic drugs in mice. Anesthesiology 2005; 102: 557-61.
6. de Vasconcellos K, Sneyd JR. Nitrous oxide: are we still in equipoise? A qualitative review of current controversies. Br J Anaesth 2013; 111: 877-85.
7. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology 2008; 109: 707-22.
8. Watcha MF, White PF. Economics of anesthetic practice. Anesthesiology 1997; 86: 1170-96.
9. Jakobsson I, Heidvall M, Davidson S. The sevoflurane-sparing effect of nitrous oxide: a clinical study. Acta Anaesthesiol Scand 1999; 43: 411-4.
10. Jang YH, Kim JW. Practical choice and knowledge of Korean anesthesiologists for fresh gas flow. Korean J Anesthesiol 2004; 46: 78-82.
11. Eger EI 2nd. Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. Anesth Analg 2001; 93: 947-53.
12. Lee SH, Shin WJ, Jeon WJ. Cost analysis of sevoflurane anesthesia compared with propofol and remifentanil infusion. Anesth Pain Med 2011; 6: 231-5.
13. Weiskopf RB, Eger EI 2nd. Comparing the costs of inhaled anesthetics. Anesthesiology 1993; 79: 1413-8.
14. Kim DK, Choi JW, Son JS, Lim HS, Ko SH, Lee SK. A comparison of the consumption of inhaled anesthetics according to fresh gas flow and anesthetic circuits. Korean J Anesthesiol 2009; 56: 125-30.